Breast cancer patients with isolated bone metastases and oligometastatic bone disease show different survival outcomes

Basit Öğe Kaydı
dc.authorscopusid35184520500
dc.authorscopusid57193273753
dc.authorscopusid6507450836
dc.authorscopusid24492648500
dc.authorscopusid57193793819
dc.authorscopusid57213835823
dc.authorscopusid57191863721
dc.authorwosidZENGEL, BAHA/GMW-8898-2022
dc.contributor.authorZengel, Baha
dc.contributor.authorKilic, Mustafa
dc.contributor.authorTasli, Funda
dc.contributor.authorSimsek, Cenk
dc.contributor.authorKaratas, Murat
dc.contributor.authorOzdemir, Ozlem
dc.contributor.authorCavdar, Demet
dc.date.accessioned2023-01-12T19:58:41Z
dc.date.available2023-01-12T19:58:41Z
dc.date.issued2021
dc.departmentN/A/Departmenten_US
dc.description.abstractIn this study, we planned to investigate the clinical course of patients with breast cancer with oligometastatic bone disease (OMBD). The patients were grouped according to the characteristics and the sites of metastases. Group I included 928 patients without metastasis. Group II, the OMBD group, included 68 patients. Group III, the widespread metastasis group, comprised 185 patients with multiple bone metastases and/or solid organ metastases. The mean overall survival of the groups was 16.7 +/- 0.3 years in group 1, and 7.8 +/- 0.8 and 5.9 +/- 0.4 years in groups 2 and 3, respectively (p < 0.001 for the comparison of all three groups together; p < 0.001 for group 1 vs. 2 and 3) and (p = 0.037 for group 2 vs. group 3). In the subgroup survival analysis of patients in group 2 (OMBD), the mean and median survival was 5.5 +/- 0.8 and 4.0 +/- 0.8 years vs. 9.2 +/- 0.98 and 9.0 +/- 1.05 years in patients with more than one bone metastasis and single bone metastasis, respectively (p = 0.019). OMBD seems to be a different disease than breast cancer with isolated bone metastases. The high risk of developing OMBD, especially following locoregional recurrence, increases the importance of locoregional therapy in large T and N stage tumors.en_US
dc.identifier.doi10.1038/s41598-021-99726-7
dc.identifier.issn2045-2322
dc.identifier.issue1en_US
dc.identifier.pmid34635748en_US
dc.identifier.scopus2-s2.0-85116786326en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.urihttps://doi.org/10.1038/s41598-021-99726-7
dc.identifier.urihttps://hdl.handle.net/11454/76994
dc.identifier.volume11en_US
dc.identifier.wosWOS:000706395800071en_US
dc.identifier.wosqualityQ2en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherNature Portfolioen_US
dc.relation.ispartofScientific Reportsen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.titleBreast cancer patients with isolated bone metastases and oligometastatic bone disease show different survival outcomesen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu